Aurora Cannabis (NASDAQ:ACB) Trading 1.5% Higher - Time to Buy?

Key Points

• Aurora Cannabis (ACB) rose about 1.5% midday to $3.48 with ~595,821 shares traded (≈2% above average); market capitalization is roughly $197 million and the 50‑day/200‑day moving averages are $3.51 and $4.31, respectively.
• Analyst sentiment is mixed: Canaccord initiated coverage with a Buy, Weiss Ratings reiterated a Sell (D-), and the three recent analyst verdicts average to a Hold.
• Recent quarterly results missed expectations—EPS $0.09 vs $0.10 estimate and revenue $68.6M vs $92.4M estimate—with a negative net margin (~23.5%); the company shows low leverage (debt/equity 0.06) and institutional ownership around 47.6%.

Aurora Cannabis Inc. (NASDAQ:ACB - Get Free Report) was up 1.5% during mid-day trading on Monday . The company traded as high as $3.52 and last traded at $3.48. Approximately 595,821 shares traded hands during trading, an increase of 2% from the average daily volume of 583,225 shares. The stock had previously closed at $3.43.

Analyst Ratings Changes

A number of research analysts have recently issued reports on ACB shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aurora Cannabis in a report on Wednesday, January 21st. Canaccord Genuity Group started coverage on shares of Aurora Cannabis in a report on Tuesday, January 27th. They set a "buy" rating for the company. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aurora Cannabis currently has an average rating of "Hold".

Aurora Cannabis Price Performance

The stock has a market capitalization of $197.28 million, a price-to-earnings ratio of -3.22 and a beta of 0.47. The business's fifty day moving average price is $3.51 and its 200-day moving average price is $4.31. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.06 and a quick ratio of 1.48.

Aurora Cannabis (NASDAQ:ACB - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.01). Aurora Cannabis had a negative return on equity of 0.04% and a negative net margin of 23.46%.The firm had revenue of $68.59 million for the quarter, compared to analysts' expectations of $92.39 million. On average, research analysts forecast that Aurora Cannabis Inc. will post 0.46 EPS for the current year.

Institutional Trading of Aurora Cannabis

Several hedge funds and other institutional investors have recently modified their holdings of the business. Virtu Financial LLC bought a new stake in shares of Aurora Cannabis in the fourth quarter valued at approximately $177,000. Mackenzie Financial Corp raised its position in shares of Aurora Cannabis by 64.3% in the fourth quarter. Mackenzie Financial Corp now owns 55,709 shares of the company's stock valued at $237,000 after purchasing an additional 21,800 shares during the period. Trexquant Investment LP bought a new stake in Aurora Cannabis during the 4th quarter worth approximately $590,000. Squarepoint Ops LLC bought a new stake in Aurora Cannabis during the 4th quarter worth approximately $69,000. Finally, Barclays PLC increased its holdings in Aurora Cannabis by 93.5% during the 4th quarter. Barclays PLC now owns 33,709 shares of the company's stock worth $142,000 after acquiring an additional 16,292 shares during the period. Institutional investors own 47.63% of the company's stock.

Aurora Cannabis Company Profile

Aurora Cannabis Inc NASDAQ: ACB is a Canadian licensed producer of medical and consumer cannabis products headquartered in Edmonton, Alberta. Established in 2013, the company operates under Health Canada's regulations to cultivate, process and distribute a range of cannabis-based offerings. Since its initial public listing in 2017, Aurora has grown into one of the country's largest growers by cultivation capacity and production output.

The company's core business spans the cultivation of dried flower, the extraction of cannabis oils and the development of value-added products such as softgels, capsules and topical treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.